AzaCITIDine

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10946 publications

A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine.

A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine.

Journal: Hematology (Amsterdam, Netherlands)

Published: April 13, 2026

5-Azacytidine incorporation into mRNAs disrupts translation and induces ribosome collisions.

5-Azacytidine incorporation into mRNAs disrupts translation and induces ribosome collisions.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Rewiring Metal-Dependent Cell Death to Unlock Immunotherapy in Colorectal Cancer.

Rewiring Metal-Dependent Cell Death to Unlock Immunotherapy in Colorectal Cancer.

Journal: Nano letters

Published: April 06, 2026

Azacitidine for MDS and CMML.

Azacitidine for MDS and CMML.

Journal: Haematologica

Published: April 01, 2026

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Journal: Experimental hematology

Published: March 29, 2026

Enhanced Remission and Survival Outcomes with Decitabine Plus Venetoclax in Additional Sex Comb Like 1 Mutated Acute Myeloid Leukemia.

Enhanced Remission and Survival Outcomes with Decitabine Plus Venetoclax in Additional Sex Comb Like 1 Mutated Acute Myeloid Leukemia.

Journal: Journal of visualized experiments : JoVE

Published: March 23, 2026

Medulloblastoma response to mevalonate pathway inhibition is independent of p53 status.

Medulloblastoma response to mevalonate pathway inhibition is independent of p53 status.

Journal: Biology direct

Published: March 11, 2026

Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia

Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 04, 2026

DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May Be a Promising Diagnostic Marker for Thyroid Cancer.

DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May Be a Promising Diagnostic Marker for Thyroid Cancer.

Journal: Thyroid : official journal of the American Thyroid Association

Published: March 04, 2026

Successful treatment of cardiac tamponade due to/pericardial infiltration with pericardial drainage and intrapericardial chemotherapy in a patient with acute myeloid leukemia

Successful treatment of cardiac tamponade due to/pericardial infiltration with pericardial drainage and intrapericardial chemotherapy in a patient with acute myeloid leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 04, 2026

DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions.

DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions.

Journal: Epigenomics

Published: February 28, 2026

Showing 1-12 of 10,946

Last Updated: 04/28/2026